Evidence map›Paper›PMID 38022872›Full record

ArticleAmerican journal of clinical and experimental immunology2023

Expression of tumoral GSK3-β, PD-L1, and CD8 cell density in urothelial carcinomas, association with tumor grade and overall survival.

Aline Kimberly Almeida Rodrigues, Paulo Goberlanio Silva, Cleto Nogueira, Samuel S Ferreira, Juliana Cordeiro, Benedito Carneiro, Fabio Tavora

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of clinical and experimental immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 64% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Aline Kimberly Almeida RodriguesICC (Ceara Cancer Institute), Laboratory of Molecular Biology and Genetics Fortaleza, CE, Brazil.
Paulo Goberlanio SilvaICC (Ceara Cancer Institute), Laboratory of Molecular Biology and Genetics Fortaleza, CE, Brazil.
Cleto NogueiraArgos Laboratory Fortaleza, CE, Brazil.
Samuel S FerreiraArgos Laboratory Fortaleza, CE, Brazil.
Juliana CordeiroArgos Laboratory Fortaleza, CE, Brazil.
Benedito CarneiroDepartment of Oncology, Brown University Providence, RI, USA.
Fabio TavoraArgos Laboratory Fortaleza, CE, Brazil.
Universidade Federal do Ceará · BRHospital Haroldo Juaçaba · BRBrown University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer is the most common malignancy in the urinary tract, and is biologically and clinically quite heterogeneous. Around 90% of diagnoses are made in the 6

objectiveTo investigate the protein expression of PD-L1 and GSK-3β and the CD8-positive immune infiltrates in bladder carcinomas. MATERIALS AND

methodsThis was a cross-sectional study of 140 samples of urothelial carcinomas from 2015 to 2018. Automated digitally assisted scoring and conventional analyses of the markers of GSK-3β (27C10), CD8 (7103β) and PDL-1 (22c3), were reviewed by two pathologists independently and a histologic score was calculated. The density of CD8 was also measured.

resultsThe immunoexpression of GSK-3β (91%) was presented in most samples, PD-L1 in 62.9% and CD8 cells present in 46.3% of cases. When analyzed in conjunction, the levels of GSK-3β and PD-L1 (P = 0.033), and CD8 and PD-L1 (P<0.002) showed significant correlations. No significant associations were observed between GSK-3β and CD8. The positivity of GSK-3β and PD-L1 was predominant in high-grade tumors.

conclusionDespite the tumor microenvironment heterogeneity, the expression of CD8, GSK-3β and PDL1 could be valuable and GSK-3β could be a potential target in advanced bladder cancer, especially in the context of immunotherapy.

Indexed as

Bladder cancerCD8glicogênio synthase kinase (GSK) 3immunohistochemistryimmunotherapyprogrammed cell death ligand 1 (PD-L1)urothelial carcinoma

Identifiers

PMID38022872
PMCPMC10658161
OpenAlexW4389180408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.